| Product Name |
Recombinant Human NRAS Protein |
| Product Overview |
This recombinant human NRAS protein includes amino acids 1-186aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
P01111 |
| Recommended Name |
GTPase NRas |
| Gene Name |
NRAS |
| Synonyms |
Neuroblastoma RAS viral (v-ras) oncogene homolog, GTPase NRas, HRAS1, ALPS4, N-ras, NRAS1, NS6 |
| Species |
Human |
| Predicted Molecular Mass |
20.8 kDa |
| Expression System |
E.coli |
| Expression Range |
1-186aa |
| Purity |
>95% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Cancer |
| Target Function |
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. |
| Subcellular Location |
Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus membrane; Lipid-anchor. |
| Protein Family |
Small GTPase superfamily, Ras family |
| Associated Diseases |
Leukemia, juvenile myelomonocytic (JMML); Noonan syndrome 6 (NS6); RAS-associated autoimmune leukoproliferative disorder (RALD); Melanocytic nevus syndrome, congenital (CMNS); Melanosis, neurocutaneous (NCMS); Keratinocytic non-epidermolytic nevus (KNEN); Thyroid cancer, non-medullary, 2 (NMTC2) |
